Product Browser

Last updated: 2016/10/23

Product Compare

Product Compare Cancel Click this icon to add products to compare list. Select up to 10 products.

Quick Order (Tutorial)

Input Catalog #,
place order here!
Catalog # :
  • Where to buy
  • Choose your location

DMBT1 Pre-design Chimera RNAi

  • Catalog # : H00001755-R06
  • Visit Frequency :
  • Countries :
  • Specification
  • Product Description:
  • Homo sapiens deleted in malignant brain tumors 1 (DMBT1), transcript variant 3, mRNA.
  • Reactivity:
  • Human
  • Supplied Product:
  • DEPC water
  • Target Refseq:
  • NM_017579
  • Storage Instruction:
  • Store at -20°C, do not exceed 4 - 5 freeze-thaw cycles to ensure product integrity.
  • Note:
  • Position of the Chimera RNAi.
    The related RNAi products listed below were designed from different accesion number but sharing the same RNAi sequence.

  • Publication Reference
  • Applications
  • RNAi Knockdown
  • Application Image
  • RNAi Knockdown
  • Gene Information
  • Entrez GeneID:
  • 1755
  • Gene Name:
  • DMBT1
  • Gene Alias:
  • GP340,MGC164738,muclin
  • Gene Description:
  • deleted in malignant brain tumors 1
  • Gene Summary:
  • Loss of sequences from human chromosome 10q has been associated with the progression of human cancers. The gene DMBT1 was originally isolated based on its deletion in a medulloblastoma cell line. DMBT1 is expressed with transcripts of 6.0, 7.5, and 8.0 kb in fetal lung and with one transcript of 8.0 kb in adult lung, although the 7.5 kb transcript has not been characterized. The DMBT1 protein is a glycoprotein containing multiple scavenger receptor cysteine-rich (SRCR) domains separated by SRCR-interspersed domains (SID). Transcript variant 2 (8.0 kb) has been shown to bind surfactant protein D independently of carbohydrate recognition. This indicates that DMBT1 may not be a classical tumor supressor gene, but rather play a role in the interaction of tumor cells and the immune system. [provided by RefSeq
  • Other Designations:
  • -
  • RSS
  • YouTube
  • Linkedin
  • Facebook